The Effect of Synthesis of Pegylated Nanoliposome Containing DNAi on Reduction of BCL-2 Gene Expression in DLCL2 Cell Line

  Non-Hodgkin lymphoma is one of the common cancers that originates from lymphatic cells. The objective of this study was to assess the effectiveness of the DNAi containing pegylated nanoliposome (antisense drug) on decrease of BCL-2 gene expression. In this study, to prepare DNAi containing pegylated nanoliposome, 3 formulations were prepared with 5, 10, and 15% combinations of PEG 2000 with certain ratios of phospholipid and cholesterols. After purification by a Zetasizer, the mean diameter of nanoliposome was measured. Drug efficacy was determined based on the standard curve of the drug. Cytotoxicity effect of the product was determined by treatment with 0.2, 0.5, and 0.8 µg/μl concentrations of each formulation in triplicate in vitro using MTT method. Then, BCL-2 gene expression was analyzed in DLCL2 cell line. Data were analyzed using one way ANOVA. The mean diameter of the DNAi containing pegylated nanoliposome was estimated to be 117 nm. The mean efficacy of the drug was 67%. The MTT assay on DLCL2 cell line indicated that the highest amount of cell growth inhibition was observed in treatment with pegylated nanoliposomes 10% (PEG10) and the concentration of 0.5 µg/μl. Also, BCL-2 gene expression was significantly decreased in DLCL2 cell line in all concentrations of PEG10 in 48 hours, and the lowest level of BCL-2 gene expression was observed in 0.5 µg/μl concentration. PEG10 nanoliposome formulation has higher efficacy in drug preservation and release compared to other two synthesized liposomes. It seems that the synthesized nanoliposome has the potential for using in pharmaceutical industries.